Trilaciclib is a Small Molecule owned by G1 Therapeutics, and is involved in 23 clinical trials, of which 10 were completed, 9 are ongoing, and 4 are planned.
Trilaciclib inhibits cyclin-dependent kinase (CDK) 4/6. CDKs govern cell cycle progression and regulate cellular from transition from G1 (growth phase) to S (DNA replication) and G2 (growth phase) to M (mitosis). G1T28 acts by inhibiting cell-cycle progression from G1 to S phase, resulting in suppression of DNA replication and decreased tumor cell proliferation which results in cells that are more resistant to DNA damage. It inhibits retinoblastoma (Rb) protein phosphorylation in early G1 stage. Inhibition of Rb phosphorylation prevents CDK-mediated G1-S phase transition, thereby arresting the cell cycle in the G1 phase, suppressing DNA synthesis and inhibiting cancer cell growth.
The revenue for Trilaciclib is expected to reach a total of $6.3bn through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Trilaciclib NPV Report.
Trilaciclib (Cosela) is a potential antineoplastic agent with chemoprotective properties. It is formulated as lyophilized cake for solution for intravenous route of administration. Cosela is indicated to decrease the incidence of chemotherapy-induced myelosuppression in adult patients when administered prior to a platinum/etoposide-containing regimen or topotecan-containing regimen for extensive-stage small cell lung cancer (ES-SCLC).
Trilaciclib is under development for the treatment of small-cell lung cancer, metastatic bladder cancer (locally advanced or metastatic urothelial carcinoma), metastatic triple negative breast cancer, colon cancer, metastatic colorectal cancer, castrate-resistant prostate cancer, NSCLC as first line and chemotherapy-induced myelosuppression. It is administered through intravenous route. The drug candidate acts by targeting cyclin-dependent kinases (CDK) 4 and 6. It was also under development for the treatment of non-small cell lung cancer.
G1 Therapeutics Overview
G1 Therapeutics is a biopharmaceutical company. It discovers, develops and commercializes therapeutics for the treatment of cancer. The company offers pipeline products that include COSELA (trilaciclib), a CDK4/6 inhibitor to preserve hematopoietic stem cell and immune system function during chemotherapy; G1T38, an oral CDK4/6 inhibitor served as backbone therapy for multiple combination regimens; Lerociclib; and G1T48, an oral selective estrogen receptor degrader. G1 Therapeutics discovers new small molecule-based methods that prevent the hematological side effects of cancer chemotherapy and exposure to ionizing radiation. The company also develops small molecules to target specific proteins associated with cell proliferation and growth. It operates through its laboratory located in Research Triangle Park. G1 Therapeutics is headquartered in Research Triangle Park, North Carolina, the US.
The company reported revenues of (US Dollars) US$31.5 million for the fiscal year ended December 2021 (FY2021), a decrease of 30.5% over FY2020. The operating loss of the company was US$142.3 million in FY2021, compared to an operating loss of US$96.5 million in FY2020. The net loss of the company was US$148.4 million in FY2021, compared to a net loss of US$99.3 million in FY2020. The company reported revenues of US$23.6 million for the third quarter ended September 2022, compared to a revenue of US$10.6 million the previous quarter.
Quick View – Trilaciclib
|Highest Development Stage|